Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

He says this breast cancer drug addresses that issue directly. "Verzenio is a tablet which we would now like to add to the treatment for certain women, and by doing so we believe it will put ...

One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...

which generally means that the manufacturer has agreed an additional discount for the drug – in this case an ex-VAT list price of £2,950 for a 56-count pack of 150mg tablets. NICE said it also ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Revenue from the breast cancer treatment Verzenio also helped in the fourth quarter, climbing 36% to $1.55 billion. Overall, Lilly’s quarterly profit swelled to $4.41 billion. Revenue advanced ...